The global cancer therapy market is estimated to be valued at USD 205.10 Bn in 2024 and is expected to exhibit a CAGR of 12.4% during the forecast period (2024-2031). Cancer continues to pose significant healthcare challenges worldwide. Rapidly aging population profiles in numerous countries have contributed to the rising cancer prevalence. Furthermore, increasing environmental pollution levels and lifestyle changes such as unhealthy diets, lack of physical activity, tobacco use, and alcohol consumption have elevated the cancer risk in populations. Despite advancements in therapeutic interventions, cancer mortality remains substantial. As a result, drug development activity in the oncology sector has intensified in recent times focused on improving patient outcomes and quality of life.
Market Dynamics:
The cancer therapy market is driven by various factors such as the increasing prevalence of cancer worldwide owing to changing lifestyle patterns, growing geriatric population, increasing adoption of targeted therapies and personalized medicine, expansion of healthcare infrastructure across emerging nations, and rising investment in cancer R&D by pharmaceutical companies. However, high treatment costs associated with cancer care pose limitations to widespread adoption. Moreover, long regulatory approval timelines for new drug approvals also challenge market growth to some extent. Meanwhile, robust cancer clinical trial pipelines and the entry of biosimilars provide significant opportunities for market expansion over the forecast period.
Key Features of the Study:
- This report provides an in-depth analysis of the global cancer therapy market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year.
- It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global cancer therapy market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study includes Bristol-Myers Squibb Company, AstraZeneca, Pfizer Inc., Novartis AG, GSK plc., Sanofi, Bayer AG, Amgen Inc., Gilead Sciences, Inc., Boehringer Ingelheim International GmbH., ADC Therapeutics SA, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Eureka Therapeutics, Inc., AbbVie Inc., Fate Therapeutics, Sorrento Therapeutics, Inc., Carrick Therapeutics Limited, Atara Biotherapeutics, Inc., Celluris, NeoTX, and Kazia Therapeutics Limited.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global cancer therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cancer therapy market.
Detailed Segmentation-
- Therapy Type:
- Chemotherapy
- Alkylating agents
- Antimetabolites
- Anti-tumor antibiotics
- Others
- Target Therapy
- Monoclonal antibodies
- Small molecule inhibitors
- Others
- Immunotherapy
- Immune Checkpoint Inhibitors
- Oncolytic virus therapy
- T-cell therapy
- Radiotherapy
- Others
- Cancer Type:
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Blood Cancer
- Liver Cancer
- Thyroid Cancer
- Head and Neck Cancer
- Skin Cancer
- Others
- Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Company Profiles:
- AstraZeneca
- Pfizer Inc.
- Novartis AG
- GSK plc.
- Sanofi
- Bayer AG
- Amgen Inc.
- Gilead Sciences, Inc.
- Boehringer Ingelheim International GmbH.
- ADC Therapeutics SA
- Hoffmann-La Roche Ltd
- Merck & Co., Inc.
- Eureka Therapeutics, Inc.
- AbbVie Inc.
- Fate Therapeutics
- Sorrento Therapeutics, Inc.
- Carrick Therapeutics Limited
- Atara Biotherapeutics, Inc.
- Celluris
- NeoTX
- Kazia Therapeutics Limited
